Why the study?
Do various pharmacotherapies influence plasma asymmetric dimethylarginine (ADMA) levels?
Do various pharmacotherapies influence plasma asymmetric dimethylarginine (ADMA) levels?
ADMA is an active player in cardiovascular disease and a potential therapeutic target, with DDAH emerging as a prime target for specific ADMA-lowering interventions.
No takes yet. Share an insight, caveat, or question.
ADMA modulation by existing drugs remains inconclusive; leaves open DDAH as a target pending prospective trials.
Renke Maas (2005) studied this question.